AGA-2118

N/A

Report date: 2024/11/08 10:47:56

Base Information

Drug NameAGA-2118
Drug Alias NameAGA-2118
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionDickkopf-related protein 1 inhibitorsSclerostin inhibitors
TargetsDickkopf-related protein 1Sclerostin
Therapy Area/IndicationsOsteoporosis, PostmenopausalOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePoland +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAngitia Biomedicines Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAngitia Incorporated LtdAngitia Biomedicines Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporosis, PostmenopausalOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A